- Last edited on April 19, 2026
Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision | |||
|
addictions:stimulants:1-use-disorder [on April 19, 2026] psychdb [Treatment] |
addictions:stimulants:1-use-disorder [on April 19, 2026] (current) psychdb [Treatment] |
||
|---|---|---|---|
| Line 197: | Line 197: | ||
| * [[meds:stimulants:home|Psychostimulants]], N-acetylcysteine, opioid agonists, disulfiram, and antidepressants have been investigated as potential treatments.[([[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302911/|Ronsley, C., Nolan, S., Knight, R., Hayashi, K., Klimas, J., Walley, A., ... & Fairbairn, N. (2020). Treatment of stimulant use disorder: a systematic review of reviews. PloS one, 15(6), e0234809.]])] | * [[meds:stimulants:home|Psychostimulants]], N-acetylcysteine, opioid agonists, disulfiram, and antidepressants have been investigated as potential treatments.[([[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302911/|Ronsley, C., Nolan, S., Knight, R., Hayashi, K., Klimas, J., Walley, A., ... & Fairbairn, N. (2020). Treatment of stimulant use disorder: a systematic review of reviews. PloS one, 15(6), e0234809.]])] | ||
| * [[meds:antidepressants:nassa:mirtazapine|Mirtazapine]] 30 mg/day for 12 weeks reduced methamphetamine use by a mean of 7 days out of 28 (vs. 4.8 days with placebo) in a phase 3, double-blind, placebo-controlled RCT [([[https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2847070|McKetin R, et al. Mirtazapine for Methamphetamine Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2026.]])] | * [[meds:antidepressants:nassa:mirtazapine|Mirtazapine]] 30 mg/day for 12 weeks reduced methamphetamine use by a mean of 7 days out of 28 (vs. 4.8 days with placebo) in a phase 3, double-blind, placebo-controlled RCT [([[https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2847070|McKetin R, et al. Mirtazapine for Methamphetamine Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2026.]])] | ||
| - | * Generally well-tolerated, though discontinuation due to adverse events was higher than placebo (23% vs 15%); common side effects included drowsiness (47% vs 33%) and weight gain (10% vs 3%) | ||
| ===== Guidelines ===== | ===== Guidelines ===== | ||
| * [[https://www.healthquality.va.gov/guidelines/MH/sud/VADODSUDCPGRevised22216.pdf|VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2015)]] | * [[https://www.healthquality.va.gov/guidelines/MH/sud/VADODSUDCPGRevised22216.pdf|VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2015)]] | ||